Abstract
BACKGROUND
Thyroid cancer is a common disease and its prevalence is increasing. Recent reports have shown that an elevated thyrotropin (thyroid stimulating hormone, TSH) level is associated with thyroid cancer risk. However, the association between TSH level and thyroid cancer risk is not yet known for euthyroid patients diagnosed with papillary thyroid microcarcinoma (PTMC). METHODS: Our study included 425 patients who underwent thyroid surgery and were diagnosed with PTMC between 2008 and 2009. Control group patients were diagnosed with benign nodules < or = 1 cm in size by US-guided fine needle aspiration. Nodules with one or more suspected malignant-ultrasonographic feature(s) were excluded from this study. Patients who were not euthyroid or who took thyroid medication were also excluded. RESULTS: The mean age of all patients was 48.5 +/- 11.0 years and 88.8% were women. The mean age of those with PTMC was significantly lower than that of the control group. The mean TSH level was 1.78 +/- 0.93 mIU/L, and the mean free T4 level was 15.96 +/- 2.32 pmol/L. There was no difference in TSH level between the PTMC and control groups (1.77 +/- 0.93 mIU/L vs. 1.79 +/- 0.91 mIU/L, P = 0.829). After adjusting for age, TSH level was not correlated with tumor size (r = 0.02, P = 0.678) in the PTMC group. Moreover, the TSH level did not differ between patients with stage I and stage III-IV carcinoma (stage I, 1.77 +/- 0.95 mIU/L; stage III-IV, 1.79 +/- 0.87 mIU/L; P = 0.856). CONCLUSION: TSH levels are not elevated in euthyroid PTMC patients. Thus, further evaluation is needed before serum TSH can be used as a tumor marker for small nodules < or = 1 cm in size in euthyroid patients.
Citations
Citations to this article as recorded by

- Could Thyroid-Stimulating Hormone Levels Predict Malignancy in Thyroid Nodules with Indeterminate Cytology? Relation between Thyroid-Stimulating Hormone Levels and Malignant Histology in Thyroid Nodules in the Indeterminate 2023 The Bethesda System for Re
Mariana Mourão, Sofia Guerreiro, Nuno Manso, Isabel Loureiro, Rosário Eusébio, Sule Canberk, Hugo Pinto Marques
Endocrinology Insights.2025; 20(3): 128. CrossRef - Effectiveness and Safety of Very-Low-Dose Rosuvastatin–Ezetimibe Therapy in Korean Patients with Dyslipidaemia: A Multicentre Prospective Observational Study
Ji Woong Roh, Moon-hwa Park, Ji-won Son, SungA Bae
Clinical Drug Investigation.2025; 45(10): 803. CrossRef - Which is the best predictor of thyroid cancer: thyrotropin, thyroglobulin or their ratio?
Pinar Yazici, Mehmet Mihmanli, Emre Bozkurt, Feyza Yener Ozturk, Mehmet Uludag
Hormones.2016; 15(2): 256. CrossRef - Evaluation of serum thyroid‐stimulating hormone as indicator for fine‐needle aspiration in patients with thyroid nodules
Ji Soo Choi, Chung Mo Nam, Eun‐Kyung Kim, Hee Jung Moon, Kyung Hwa Han, Jin Young Kwak
Head & Neck.2015; 37(4): 498. CrossRef